NASDAQ: BBOTBridgebio Oncology Therapeutics Inc Stock
$8.42-0.14 (-1.64%)
Updated Jul 20, 2026
BBOT Price
$8.42
Fair Value Price
$11.91
Market Cap
$674.50M
52 Week Low
$7.01
52 Week High
$14.87
P/E
-0.01x
P/B
1.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$154.10M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$149M
Beta
0.33
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BBOT Overview
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BBOT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BBOT
Ranked#407 of 464
Ranked#407 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $243.47 | A | |
| $11.15 | A | |
| $8.60 | A |
Be the first to know about important BBOT news, forecast changes, insider trades & much more!
BBOT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BBOT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BBOT ($8.42) is undervalued by 29.3% relative to our estimate of its Fair Value price of $11.91 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BBOT ($8.42) is significantly undervalued by 29.3% relative to our estimate of its Fair Value price of $11.91 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BBOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BBOT due diligence checks available for Premium users.
Valuation
BBOT fair value
Fair Value of BBOT stock based on Discounted Cash Flow (DCF)
Price
$8.42
Fair Value
$11.91
Undervalued by
29.30%
BBOT ($8.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BBOT ($8.42) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BBOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BBOT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
21.5x
Market
11.71x
BBOT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.81x
Industry
5.33x
BBOT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BBOT's financial health
Profit margin
Revenue
$0.0
Net Income
-$42.1M
Profit Margin
0%
BBOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$417.6M
Liabilities
$45.4M
Debt to equity
0.12
BBOT's short-term assets ($266.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBOT's short-term assets ($266.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBOT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.9M
Investing
-$285.4M
Financing
$295.0k
BBOT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BBOT vs Biotech Stocks
Bridgebio Oncology Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.